Poornima Ramadas, MBBS | Ochsner LSU Health

Dr. Poornima Ramadas

Claim this profile

LSU Health Sciences Center at Shreveport

Studies Multiple Myeloma
Studies Lymphoma
7 reported clinical trials
20 drugs studied

Area of expertise

1Multiple Myeloma
Poornima Ramadas has run 3 trials for Multiple Myeloma. Some of their research focus areas include:
Stage I
Stage II
Stage III
2Lymphoma
Poornima Ramadas has run 2 trials for Lymphoma. Some of their research focus areas include:
13q positive
13q negative
12 positive

Affiliated Hospitals

Image of trial facility.
LSU Health Sciences Center At Shreveport
Image of trial facility.
Ochsner LSU Health Monroe Medical Center

Clinical Trials Poornima Ramadas is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria

More about Poornima Ramadas

Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Poornima Ramadas has experience with
  • Lenalidomide
  • Dexamethasone
  • Venetoclax
  • Obinutuzumab
  • Cyclophosphamide
  • Oral Azacitidine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Poornima Ramadas specialize in?
Is Poornima Ramadas currently recruiting for clinical trials?
Are there any treatments that Poornima Ramadas has studied deeply?
What is the best way to schedule an appointment with Poornima Ramadas?
What is the office address of Poornima Ramadas?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security